Italian cancer figures - Report 2013 Multiple tumours;I Tumori in Italia - Rapporto 2013 Tumori multipli

Epidemiologia e Prevenzione

Volumn 37, Issue 4-5, 2013, Pages 1-156

  Buzzoni, Carlotta ^a   Crocetti, Emanuele ^a   Bella, Francesca ^b   Bonelli, Luigina ^c   Caldarella, Adele ^a   Castaing, Marine ^b   Cercato, Maria Cecilia ^d   Dal Maso, Luigino ^e   Dei Tos, Angelo Paolo ^f   Ferretti, Stefano ^g   Giacomin, Adriano ^h   Pannozzo, Fabio ⁱ   Mazzoleni, Guido ^j   Patriarca, Silvia ^k   Petrucci, Saba ^l   Pisani, Paola ^m   de Leon, Maurizio Ponz ⁿ   Quaglia, Alberto ^c   Ramazzotti, Valerio ^d   Tumino, Rosario ^o   Vercelli, Marina ^c,p   more..

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f Registro Tumori del Veneto   (Italy)

^g UNIVERSITY OF FERRARA   (Italy)

^h Centro di riferimento regionale per l epidemiologia e la prevenzione dei tumori   (Italy)

ⁱ Registro Tumori di Popolazione della Provincia di Latina   (Italy)

^j Registro Tumori dell'Alto Adige   (Italy)

^k MOLINETTE HOSPITAL   (Italy)

^l UNIVERSITY OF PERUGIA   (Italy)

^m CPO Piemonte   (Italy)

ⁿ Policlinico universitario   (Italy)

^o Azienda sanitaria provinciale   (Italy)

^p UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

Cancer; Italy; Registries; Risk assessment; Second primary

Indexed keywords

ADOLESCENT; ADULT; AGED; CHILD; COHORT ANALYSIS; EPIDEMIOLOGY; FEMALE; HUMAN; INCIDENCE; INFANT; ITALY; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; INCIDENCE; INFANT; ITALY; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84922481790     PISSN: 11209763     EISSN: 23851937     Source Type: Journal    
DOI: None     Document Type: Article

References (148)

1. www.registri-tumori.it
2. AIRTUMWorking Group; CCM; AIEOPWorking Group. Italian cancer figures, report 2012: Cancer in children and adolescents. Epidemiol Prev 2013;37(1) Suppl 1:1-225.
3. AIRTUM Working Group. Italian cancer figures, report 2011: Survival of cancer patients in Italy. Epidemiol Prev 2011;35(5-6) Suppl 3:1-200.
4. AIRTUMWorking Group. Italian cancer figures, report 2010: Cancer prevalence in Italy. Patients living with cancer, long-term survivors and cured patients. Epidemiol Prev 2010;34(5-6) Suppl 2:1-188.
5. http://www.registri-tumori.it/cms/files/Protocollo2010.pdf
6. Crocetti E, Lecker S, Buiatti E, Storm HH. Problems related to the coding of multiple primary cancers. Eur J Cancer 1996;32A(8):1366-70.
7. Buiatti E, Crocetti E, Gafà L et al. Agreement estimate among three Italian cancer registries in the coding of multiple primary cancers. Tumori 1996;82(6):533-8.
8. Buiatti E, Crocetti E, Acciai S et al. Incidence of second primary cancers in three Italian population-based cancer registries. Eur J Cancer 1997;33(11):1829-34.
9. Crocetti E, Buiatti E, Falini P; Italian Multiple Primary Cancer Working Group. Multiple primary cancer incidence in Italy. Eur J Cancer 2001;37(18):2449-56.
10. Fritz A, Percy C, Jack A et al (eds). International classification of diseases for Oncology. Third Edition. Geneva, World Health Organization, 2000.
11. Patriarca S, Gafà L, Ferretti S et al. Coding criteria of bladder cancer: effects on estimating survival. Epidemiol Prev 2001;25(3) Suppl:42-7.
12. IACR-IARC. International rules for multiple primary cancers. Third edition. International Report No. 2004/02. Lione, IARC, 2004. Available at: http://www.iacr.com.fr/MPrules_july2004.pdf
13. http://www.registri-tumori.it/cms/it/node/372
14. Curtis RE, Boice JD Jr, Kleinerman RA, Flannery JT, Fraumeni JF Jr. Summary: multiple primary cancers in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985;68:219-42.
15. Breslow NE, Day NE. Statistical methods in cancer research. Volume II - The design and analysis of cohort studies. IARC Sci Publ 1987;(82):1-406.
16. http://seer.cancer.gov/seerstat/
17. Curtis RE, Boice JD Jr, Kleinerman RA, Flannery JT, Fraumeni JF Jr. Summary: multiple primary cancers in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985;68:219-42.
18. Heard A, Roder D, Luke C. Multiple primary cancers of separate organ sites: implications for research and cancer control (Australia). Cancer Causes Control 2005;16(5):475-81.
19. Curtis RE, Freedman DM, Ron E et al (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH Publ. No. 05-5302. Bethesda (MD), National Cancer Institute, 2006.
20. Levi F, Randimbison L, Te VC, Rolland-Portal I, Franceschi S, La Vecchia C. Multiple primary cancers in the Vaud Cancer Registry, Switzerland, 1974-89. Br J Cancer 1993;67(2):391-5.
21. Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer 2011;11:83.
22. Cluze C, Delafosse P, Seigneurin A, Colonna M. Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study. Eur J Cancer Prev 2009;18(5): 343-8.
23. Tsukuma H, Fujimoto I, Hanai A, Hiyama T, Kitagawa T, Kinoshita N. Incidence of second primary cancers in Osaka residents, Japan, with special reference to cumulative and relative risks. Jpn J Cancer Res 1994;85(4):339-45.
24. Coleman MP. Multiple primary malignant neoplasms in England and Wales, 1971-1981. Yale J Biol Med 1986;59(5):517-31.
25. Teppo L, Pukkala E, Saxén E. Multiple cancer - an epidemiologic exercise in Finland. J Natl Cancer Inst 1985;75(2):207-17.
26. Karahalios E, English D, Thursfield V, Simpson J, Farrugia H, Graham G. Second primary cancers in Victoria. Melbourne, Victorian Cancer Registry, Cancer Epidemiology Centre, CAncer Council Victoria, 2009. Available at: http://www.cancervic.org.au/about-our-research/ epidemiology/second-primary-cancers-victoria
27. Crocetti E, Lecker S, Buiatti E, Storm HH. Problems related to the coding of multiple primary cancers. Eur J Cancer 1996;32A(8):1366-70.
28. Buiatti E, Crocetti E, Gafà L et al. Agreement estimate among three Italian cancer registries in the coding of multiple primary cancers. Tumori 1996;82(6):533-8.
29. Buiatti E, Crocetti E, Acciai S et al. Incidence of second primary cancers in three Italian population-based cancer registries. Eur J Cancer 1997;33(11):1829-34.
30. Crocetti E, Buiatti E, Falini P; Italian Multiple Primary Cancer Working Group. Multiple primary cancer incidence in Italy. Eur J Cancer 2001;37(18):2449-56.
31. Crocetti E, Guzzinati S, Paci E et al. The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of Cancer Registries). Melanoma Res 2008;18(3):230-4.
32. AIRTUMWorking Group. Italian cancer figures, report 2011:Survival of cancer patient in Italy. Epidemiol Prev 2011;35(5-6) Suppl 3:1-200.
33. Crocetti E, Buiatti E. Re: multiple neoplasias: an oncologic reality. J Natl Cancer Inst 1997;89(21):1634-6.
34. Pheby D, Martinez C, Roumagnac M, Schouten L. Recommendations for coding Multiple Primaries. 2000. Available at: http://www.encr.com.fr/multpeng.pdf
35. Curado MP, Edwards B, Shin HR et al (eds). Cancer Incidence in Five Continents, Vol. IX. IARC Scientific publications n.160. Lyon 2007.
36. Statistiche demografiche ISTAT. Available at: http://demo.istat.it/ bil2002/index.html
37. Goodman SN. Multiple comparisons, explained. Am J Epidemiol 1998;147(9):807-12.
38. Hemminki K, Boffetta P. Multiple primary cancers as clues to environmental and heritable causes of cancer and mechanisms of carcinogenesis. IARC Sci Publ 2004;(157):289-97.
39. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21(3):427-33.
40. World Cancer Research Fund; American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington (DC), AICR, 2007.
41. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review andmeta-analysis of prospective observational studies. Lancet 2008;371(9612):569-78.
42. Ahsan H, Insel BJ, Neugut AI. Risk estimates for second primary cancers. In: Neugut AI, Meadows AT, Robinson E (eds).Multiple primary cancers. Philadelphia (PA), Lippincott Williams and Wilkins, 1999; pp. 27-53.
43. Schatzkin A, Baranovsky A, Kessler LG. Diet and cancer. Evidence from associations of multiple primary cancers in the SEER program. Cancer 1988;62(7):1451-7.
44. Neugut AI, Murray TI, Lee WC, Robinson E. The association of breast cancer and colorectal cancer in men. An analysis of Surveillance, epidemiology, and results program data. Cancer 1991;68(9):2069-73.
45. Pinto BM, Trunzo JJ. Health behaviours during and after a cancer diagnosis. Cancer 2005;104(11) Suppl:2614-23.
46. Kellen E, Zeegers MP, Dirx M et al. Occurrence of both bladder and prostate cancer in five cancer registries in Belgium, The Netherlands and the United Kingdom. Eur J Cancer 2007;43(11):1694-700.
47. Chaturvedi AK, Kleinerman RA, Hildesheim A et al. Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol 2009;27(6):967-73.
48. Hisada M, Rabkin CS. Viral causes of cancer. In: Shields PG (ed). Cancer risk assessment. Boca Raton, Taylor & Francis, 2005; pp. 287-311.
49. van Leeuwen FE, Travis LB. Second cancers. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer Principles and Practice of Oncology, 6th ed. Philadelphia, Lippincott Williams & Wilkins, 2001; pp. 2939-64.
50. Travis LB, Gospodarowicz M, Curtis RE et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94(3):182-92.
51. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Jr. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 2002;158(2):220-35.
52. Crocetti E, Paci E. Prevalence of hysterectomy and its effect on uteran cancer incidence rates. Gynecol Oncol 2000;79(2):337-8.
53. Boice JD Jr, Day NE, Andersen A et al. Second cancer following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst 1985;74(5):955-75.
54. Kerber RA, O'Brien E. A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer 2005;103(9):1906-15.
55. Lin KM, Shashidharan M, Thorson AG et al. Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2mutation carriers of hereditary nonpolyposis colorectal cancer. J Gastrointest Surg 1998;2(1):67-71.
56. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96(4):261-8.
57. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71(4): 747-52.
58. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90(8):606-11.
59. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91(15):1310-6.
60. Bachmann IM, Halvorsen OJ, Collett K et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24(2):268-73.
61. Poppema S. Immunology of Hodgkin's disease. Baillieres Clin Haematol 1996;9(3):447-57.
62. No authors listed. Cancer survivors: living longer, and now, better. Lancet 2004;364(9452):2153-4.
63. Travis LB, Rabkin CS, Brown LM et al. Cancer survivorship - genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006;98(1):15-25.
64. Crocetti E, Buiatti E, Falini P; Italian Multiple Primary Cancer Working Group.Multiple primary cancer incidence in Italy. Eur J Cancer 2001; 37(18):2449-56.
65. Cercato MC, Colella E, Ferraresi V, Diodoro MG, Tonachella R. Report of two cases of quintuple primarymalignancies and review of the literature. Anticancer Res 2008;28(5B):2953-8.
66. Aydiner A, Karadeniz A, Uygun K et al.Multiple primary neoplasms at a single institution: differences between synchronous and metachronous neoplasms. Am J Clin Oncol 2000;23(4):364-70.
67. Demandante CG, Troyer DA, Miles TP. Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. Am J Clin Oncol 2003;26(1):79-83.
68. AIRTUM Working Group. Italian Cancer Figures, Report 2009: Cancer trend (1998-2005). Epidemiol Prev 2009;33(4-5) Suppl 1: 1-168.
69. Dal Maso L, Lise M, Zambon P et al; AIRTUM Working Group. Incidence of thyroid cancer in Italy, 1991-2005: time trends and age-period- cohort effects. Ann Oncol 2011;22(4):957-63.
70. Rosso S, De Angelis R, Ciccolallo L et al; EUROCARE Working Group. Multiple tumours in survival estimates. Eur J Cancer 2009; 45(6):1080-94.
71. Matzkin H, Braf Z. Multiple primarymalignant neoplasms in the genitourinary tract: occurrence and etiology. J Urol 1989;142(1):1-12.
72. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005;23(2):276-92.
73. Hemminki K, Granstrom C. Familial clustering of ovarian and endometrial cancers. Eur J Cancer 2004;40(1):90-5.
74. Lee M, Pellegata NS. Multiple endocrine neoplasia syndromes associated with mutation of p27. J Endocrinol Invest 2013 [Epub ahead of print].
75. Kast K, Krause M, Schuler M et al. Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature. BMC Cancer 2012;12:217.
76. http://apps.who.int/bookorders/WHP/home1.jsp?sesslan=1
77. Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG (eds). Cancer Registration: Principles and Methods. IARC Scientific Publications n.95. Lyon, IARC, 1991.
78. World Health Organization. WHO Handbook for Standardized Cancer Registries. Geneva, WHO, 1976.
79. Berg JW. Morphologic classification of human cancer. In: Schottenfeld D, Fraumeni JF Jr (eds). Cancer Epidemiology and Prevention. Philadelphia, Saunders, 1982; pp.74-9.
80. Berg JW. Morphologic classification of human cancer. In: Schottenfeld D, Fraumeni JF Jr (eds). Cancer Epidemiology and Prevention. 2nd edition. Chapter 3, Section 1: Basic Concepts. Oxford, New York, Oxford University Press, 1996; pp. 28-44.
81. Percy C, Van Holten V, Muir C (eds). International Classification of Diseases for Oncology. 2nd Edition. Geneva, WHO, 1990.
82. Fritz A, Jack A, Parkin DM et al (eds). International Classification of Diseases for Oncology. 3rd Edition. Geneva, WHO, 2000.
83. International Agency for Research on Cancer. International rules for multiple primary cancers (ICD-O Third Edition). Internal report No. 2004/02. Lyon, IARC, 2004. Available at: http://www.iacr.com.fr/ Mprules_july2004.pdf
84. International Agency for Researc on Cancer; World Health Organization. Updates to the International Classification of Diseases for Oncology, third edition (ICD-O-3). IARC/WHO 2011. Available at: ht tp: / /www.who. int /classi f icat ions/ icd/updates/ ICDO3 Updates2011.pdf
85. Crocetti E, Buiatti E. Re: multiple neoplasias: an oncologic reality. J Natl Cancer Inst 1997;89(21):1634-6.
86. Curado MP, Edwards B, Shin HR et al. (eds). Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Pubblication No. 160. Lyon, IARC, 2007.
87. http://seer.cancer.gov/tools/mphrules/
88. Parkin DM, Plummer M. Comparability and quality of data. In: Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds). Cancer Incidence in Five Continents, Vol. VIII. IARC Scientific Pubblication No. 155; pp. 57-74. Lyon, IARC, 2002.
89. http://seer.cancer.gov/tools/mphrules/revisions.html
90. Ferretti S, Giacomin A; Gruppo di lavoro AIRTUM. Manuale di tecniche di registrazione dei tumori. Milano, Inferenze Editore, 2008.
91. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005; 331(7515):481.
92. Dal Maso L, Lise M, Zambon P et al; AIRTUM Working Group. Incidence of thyroid cancer in Italy, 1991-2005: time trends and age-period- cohort effects. Ann Oncol 2011;22(4):957-63.
93. Curtis RE, Boice JD Jr, Kleinerman RA, Flannery JT, Fraumeni JF Jr. Summary: multiple primary cancers in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985;68:219-42.
94. Curtis RE, Freedman DM, Ron E et al (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH Publ No. 05-5302. Bethesda (MD), National Cancer Institute, 2006.
95. Storm HH, Jensen OM, Ewertz M et al. Summary: multiple primary cancers in Denmark, 1943-80. Natl Cancer Inst Monogr 1985; 68:411-30.
96. Levi F, Randimbison L, Te VC, Rolland-Portal I, Franceschi S, La Vecchia C. Multiple primary cancers in the Vaud Cancer Registry, Switzerland, 1974-89. Br J Cancer 1993;67(2):391-5.
97. Crocetti E, Buiatti E, Falini P; Italian Multiple Primary Cancer Working Group. Multiple primary cancer incidence in Italy. Eur J Cancer 2001;37(18):2449-56.
98. Tsukuma H, Fujimoto I, Hanai A, Hiyama T, Kitagawa T, Kinoshita N. Incidence of second primary cancers in Osaka residents, Japan, with special reference to cumulative and relative risks. Jpn J Cancer Res 1994;85(4):339-45.
99. Tabuchi T, Ito Y, Ioka A, Miyashiro I, Tsukuma H. Incidence of metachronous second primary cancers in Osaka, Japan: update of analyses using population-based cancer registry data. Cancer Sci 2012;103(6):1111-20.
100. Teppo L, Pukkala E, Saxén E. Multiple cancer - an epidemiologic exercise in Finland. J Natl Cancer Inst 1985;75(2):207-17.
101. Coleman MP. Multiple primary malignant neoplasms in England and Wales, 1971-1981. Yale J Biol Med 1986;59(5):517-31.
102. Karahalios E, English D, Thursfield V, Simpson J, Farrugia H, Giles G. Second primary cancers in Victoria. Victorian Cancer Registry, Cancer Epidemiology Centre, The Cancer Council of Victoria, Australia. Melbourne 2009. Available at: http://www.cancervic.org.au/aboutour- research/epidemiology/second-primary-cancers-victoria
103. Curado MP, Edwards B, Shin HR et al. Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publication No. 160. Lyon, IARC, 2007.
104. Berrino F, Verdecchia A, Lutz JM, Lombardo C, Micheli A, Capocaccia R; EUROCAREWorking Group. Comparative cancer survival information in Europe. Eur J Cancer 2009, 45(6):901-8.
105. Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer 2011;11:83.
106. Cluze C, Delafosse P, Seigneurin A, Colonna M. Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study. Eur J Cancer Prev 2009;18(5): 343-8.
107. Heard A, Roder D, Luke C. Multiple primary cancers of separate organ sites: implications for research and cancer control (Australia). Cancer Causes Control 2005;16(5):475-81.
108. Puliti D, Duffy SW, Miccinesi G et al; EUROSCREEN Working Group. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen 2012;19 Suppl 1:42-56.
109. Breslow N, Chan CW, Dhom G et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977;20(5):680-8.
110. Sobrinho-Simôes MA, Sambade MC, Gonçalves V. Latent thyroid carcinoma at autopsy: a study from Oporto, Portugal. Cancer 1979; 43(5):1702-6.
111. Morrison AS. Screening in chronic disease. New York, Oxford University Press, 1992.
112. Crocetti E, Buiatti E. Re: multiple neoplasias: an oncologic reality. J Natl Cancer Inst 1997;89(21):1634-6.
113. http://seer.cancer.gov/siterecode/icdo3_d01272003/
114. Swerdlow SH, Campo E, Harris NL et al (eds).WHO Classification of tumours of Hematopoietic and Lymphoid Tissues. Lyon, IARC, 2008.
115. Fritz A, Percy C, Jack A, et al (eds). International Classification of Disease for Oncology, third edition. Geneva, WHO, 2000.
116. Tavani A, Pregnolato A, Negri E, et al. Diet and risk of lymphoid neoplasms and soft tissue sarcomas. Nutr Cancer 1997;27(3):256-60.
117. Miligi L, Costantini AS, Veraldi A, Benvenuti A;WILL, Vineis P. Cancer and pesticides: an overview and some results of the Italian multicenter case-control study on hematolymphopoietic malignancies. Ann N Y Acad Sci 2006;1076:366-77.
118. Liu H, Hemminki K, Sundquist J. Renal cell carcinoma as first and second primary cancer: etiological clues from the Swedish Family- Cancer Database. J Urol 2011;185(6):2045-9.
119. Tanaka H, Tsukuma H, Teshima H et al. Second primary cancers following non-Hodgkin's lymphoma in Japan: increased risk of hepatocellular carcinoma. Jpn J Cancer Res 1997;88(6):537-42.
120. Nielsen SF, Nordestgaard BG, Bojesen SE. Associations between first and second primary cancers: a population-based study. CMAJ 2012;184(1):E57-69.
121. Ariad S, Lewis D, Bezwoda WR. Kaposi's sarcoma after alpha-interferon treatment for HIV-negative T-cell lymphoma. S Afr Med J 1993;83(6):430-1.
122. Tward J, Glenn M, Pulsipher M, Barnette P, Gaffney D. Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2007;48(8):1482-95.
123. Ulbright TM, Santa Cruz DJ. Kaposi's sarcoma: relationship with hematologic, lymphoid, and thymic neoplasia. Cancer 1981;47(5): 963-73.
124. Subramanian S, Goldstein DP, Parlea L et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 2007;17(12):1277-88.
125. Sawka AM, Thabane L, Parlea L et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009;19(5):451-7.
126. www.who.int/classifications/icd/revision/en/
127. Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013;10(5):289-301.
128. Andersson M, Jensen MB, Engholm G, Storm H. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001. Acta Oncol 2008;47(4):755-64.
129. Royle JS, Baade P, Joske D, Fritschi L. Risk of second cancer after lymphohematopoietic neoplasm. Int J Cancer 2011;129(4):910-9.
130. Henson KE, McGale P, Taylor C, Darby SC. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer 2013; 108(1):179-82.
131. Morton LM, Gilbert ES, Hall P et al. Risk of treatment-related esophageal cancer among breast cancer survivors. Ann Oncol 2012;23(12):3081-91.
132. Curtis RE, Boice JD Jr, Stovall M et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992;326(26):1745-51.
133. Morton LM, Dores GM, Tucker MA et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 2013;121(15): 2996-3004.
134. Hershman D, Neugut AI, Jacobson JS et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colonystimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007;99(3):196-205.
135. Davies C, Pan H, Godwin J et al; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381(9869):805-16.
136. Jones ME, van Leeuwen FE, Hoogendoorn WE et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res 2012;14(3):R91.
137. Dores GM, Anderson WF, Beane Freeman LE, Fraumeni JF Jr, Curtis RE. Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapy. Br J Cancer 2010;103(7):1081-4.
138. Swerdlow AJ, Cooke R, Bates A et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. J Clin Oncol 2012;30(22):2745-52.
139. Colin C, de Vathaire F, Noël A et al. Updated relevance of mammographic screening modalities in women previously treated with chest irradiation for Hodgkin disease. Radiology 2012;265(3):669-76.
140. Win AK, Lindor NM, Young JP et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst 2012;104(18):1363-72.
141. Vasen HF, Blanco I, Aktan-Collan K et al; Mallorca group. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013; 62(6):812-23.
142. Metcalfe KA, Lynch HT, Ghadirian P et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 2005;96(1):222-6.
143. Mavaddat N, Peock S, Frost D et al; EMBRACE. Cancer Risks for BRCA1 and BRCA2mutation carriers: results fromprospective analysis of EMBRACE. J Natl Cancer Inst 2013;105(11):812-22.
144. Reis-Filho JS, Tutt AN. Triple negative tumors: a critical review. Histopathology 2008;52(1):108-18.
145. Lips EH, Mulder L, Oonk A et al. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer 2013;108(10):2172-7.
146. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL. Clinical implications and utility of field cancerization. Cancer Cell Int 2007;7:2.
147. Roesch-Ely M, Nees M, Karsai S et al. Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 2007;26(1):54-64.
148. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102(9):605-13.